Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

120 projects found matching your search criteria :

  1. Simultaneous stimulation of muscarinic M4 receptor and selected receptors involved in the regulation of glutamate releas...

    Call: OPUS 9 , Panel: NZ7

    Principal investigator: dr hab. Joanna Monika Wierońska

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  2. Targeted inhibition of STATs and IRFs as a novel treatment strategy in cardiovascular disease

    Call: OPUS 9 , Panel: NZ2

    Principal investigator: prof. Johannes Antonius Bluijssen (Bluyssen)

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Biologii

  3. Next generation in vitro experimental model of melanoma for pharmacological studies

    Call: OPUS 8 , Panel: NZ7

    Principal investigator: prof. Małgorzata Ewa Czyż

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  4. Efficacy, toxicity and immunogenicity of carriers made of bioengineered spider silk for targeted drug delivery

    Call: OPUS 8 , Panel: NZ7

    Principal investigator: dr hab. Hanna Dams-Kozłowska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Medyczny

  5. Identification of new, clinically relevant genetic and epigenetic aberrations by next-generation sequencing in chronic m...

    Call: HARMONIA 6 , Panel: NZ5

    Principal investigator: dr Tomasz Artur Stokłosa

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  6. Identification of proline metabolic pathway as a molecular target for experimental regulation of apoptosis/autophagy in ...

    Call: OPUS 7 , Panel: NZ7

    Principal investigator: prof. Jerzy Aleksander Pałka

    Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

  7. Research on human eosinophils as a potential therapeutic target.

    Call: PRELUDIUM 7 , Panel: NZ7

    Principal investigator: Marek Rafał Grosicki

    Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum; Wydział Farmaceutyczny

  8. Characteristics of neuropilin-1 (NRP1) as a target of antiangiogenic activity of immunomodulatory drugs in multiple myel...

    Call: OPUS 7 , Panel: NZ6

    Principal investigator: prof. Krzysztof Giannopoulos

    Uniwersytet Medyczny w Lublinie, II Wydział Lekarski z Oddziałem Anglojęzycznym

  9. Physicochemical characterization of cyclodextrins tailored for pH-dependent targeted therapy with anthracycline drugs

    Call: OPUS 7 , Panel: ST5

    Principal investigator: prof. Renata Bilewicz

    Uniwersytet Warszawski, Wydział Chemii

  10. New drug carriers in targeted anticancer therapy

    Call: OPUS 1 , Panel: ST5

    Principal investigator: prof. Artur Piotr Terzyk

    Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Chemii

  11. GPR18 orphan receptor. Search for the tools to investigate GPR18 as potential therapeutic target

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: prof. Katarzyna Justyna Kieć-Kononowicz

    Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum; Wydział Farmaceutyczny

  12. Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

    Call: OPUS 6 , Panel: NZ7

    Principal investigator: dr hab. Sylwia Flis

    Narodowy Instytut Leków

  13. Cross-talk between PXR and AR receptors in hormone-dependent cancers.

    Call: SONATA 5 , Panel: NZ7

    Principal investigator: dr Magdalena Niemira

    Politechnika Gdańska, Wydział Chemiczny

  14. Characteristics of the cell wall hydrolases of pathogenic bacteria Listeria monocytogenes and their partcipation in the ...

    Call: OPUS 5 , Panel: NZ6

    Principal investigator: dr hab. Magdalena Anna Popowska

    Uniwersytet Warszawski, Wydział Biologii

  15. Transcription factor MeCP2 as an intracellular object of study on the mechanism of depression and as a potential pharmac...

    Call: SONATA 5 , Panel: NZ7

    Principal investigator: dr Magdalena Jolanta Sowa-Kućma

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  16. Mitochondrial aldehyde dehydrogenase (ALDH2) as a new target for anti-atherosclerotic drugs

    Call: PRELUDIUM 1 , Panel: NZ4

    Principal investigator: Aneta Olga Stachowicz

    Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum; Wydział Lekarski

  17. Preparation and physico-chemical evaluation of mesoporous oxide matrices as carriers in a model of the implant to the bo...

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: prof. Wiesław Stanisław Sawicki

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

  18. Evaluation of peroxiredoxins 1 and 2 along with the thioredoxin-thioredoxin reductase system as new therapeutic targets ...

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: dr hab. Radosław Zagożdżon

    Warszawski Uniwersytet Medyczny, I Wydział Lekarski

  19. DNA double-stranded break repair proteins as a target for personalized cancer therapy based on synthetic lethality

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Śliwiński

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  20. PHARMACOTHERAPY OF OSTEOARTHRITIS: TRPV1 AND CB1 RECEPTORS AND THEIR ENDOGENOUS LIGANDS AS NEW TARGETS FOR PHARMACOLOGIC...

    Call: SONATA BIS 2 , Panel: NZ7

    Principal investigator: dr hab. Katarzyna Maria Starowicz-Bubak

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  21. The group III metabotropic glutamate receptors as a target for future antypsychotic drugs

    Call: MAESTRO 3 , Panel: NZ7

    Principal investigator: prof. Andrzej Pilc

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  22. The study of the role of mGluR8 in cancer cells - a potential target for new antitumor strategies

    Call: OPUS 3 , Panel: NZ3

    Principal investigator: dr Danuta Jantas

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  23. Multitasking polymeric lattices included selected DNA oligonucleotide sequences - synthesis, modifications and physioche...

    Call: SONATA 3 , Panel: ST5

    Principal investigator: dr Ewelina Zabost

    Uniwersytet Warszawski, Wydział Chemii

  24. The role of EZH2 activity in the development of resistance to targeted therapy in melanoma

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: dr Michał Jerzy Woźniak

    Uniwersytet Medyczny w Łodzi

  25. Janus nanoparticles - research on the effect of the duality of carriers of the activesubstance in targeted therapy of sk...

    Call: OPUS 28 , Panel: ST8

    Principal investigator: dr hab. Bożena Anna Tyliszczak

    Politechnika Krakowska im. Tadeusza Kościuszki

  26. Selective autophagy-mediated protein degradation as a potential therapeutic strategy for the treatment of inflammatory c...

    Call: OPUS 28 , Panel: NZ7

    Principal investigator: dr hab. Monika Emilia Marcinkowska

    Uniwersytet Jagielloński

  27. M6A RNA methylation signatures as a targets for HPV-dependent HNSCC therapy

    Call: OPUS 27 , Panel: NZ5

    Principal investigator: Kamila Ostrowska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  28. The Potential of Mycobacterium tuberculosis Phase-Specific Antigens for Targeted TB Diagnosis

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: dr Shima Mahmoudi

    Politechnika Śląska

  29. Disruption of the posttranslational activation of the translation factor EF-P as a new target for antimicrobial agents.

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: dr Piotr Wilk

    Uniwersytet Jagielloński

  30. Small molecule modulators of the tumor necrosis factor alpha signaling pathway for the inhibition of inflammatory proces...

    Call: OPUS 27 , Panel: NZ7

    Principal investigator: prof. Tadeusz Holak

    Uniwersytet Gdański

  31. Precision double strike against non-small cell lung cancer. Insights into multidirectional therapies and the landscape o...

    Call: OPUS 27 , Panel: NZ5

    Principal investigator: dr Katarzyna Anna Malarz

    Politechnika Śląska

  32. Stimuli-responsive anion transporters for targeted drug delivery

    Call: OPUS 26 , Panel: ST5

    Principal investigator: dr hab. Michał Jan Chmielewski

    Uniwersytet Warszawski, Centrum Nauk Biologiczno-Chemicznych

  33. Restoring Beta-cell Integrity through Targeted SPOP Inhibition and PDX-1 Preservation

    Call: OPUS 26 (LAP) , Panel: NZ7

    Principal investigator: dr Anna Czarna

    Uniwersytet Jagielloński, Małopolskie Centrum Biotechnologii Uniwersytetu Jagiellońskiego

  34. Integrated multi-omics approach to accelerate anticancer drug discovery by targeting metabolic reprogramming in human co...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Danuta Dudzik

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

  35. PROteolysis TArgeting Chimeras (PROTACs) intended to knock down excessive amyloidogenic proteins, human islet amyloid po...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr hab. Elżbieta Jankowska

    Uniwersytet Gdański, Wydział Chemii

  36. The inhibition of NMDAR and TRPM4 coupling - a hope for novel therapeutic target for the treatment of the ischemic brain...

    Call: SONATA BIS 13 , Panel: NZ7

    Principal investigator: dr Bartosz Sebastian Pomierny

    Uniwersytet Jagielloński, Collegium Medicum

  37. Deciphering the Chemoproteomics and Chemotranscriptomics of Anti-Alzheimer Drugs for Novel Druggable Target Identificati...

    Call: WEAVE-UNISONO , Panel: NZ5

    Principal investigator: prof. Krzysztof Sobczak

    Uniwersytet im. Adama Mickiewicza w Poznaniu

  38. Directed screening and evaluation of novel bactericidal compounds active againsttubercle bacilli and Mycobacterium absce...

    Call: OPUS 25 , Panel: NZ7

    Principal investigator: prof. Jarosław Dziadek

    Instytut Biologii Medycznej Polskiej Akademii Nauk

  39. Curdlan-based biomaterial as a nanostructure carrier for controlled and targeted drug delivery in the treatment of deep ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: dr Aleksandra Nurzyńska

    Uniwersytet Medyczny w Lublinie

  40. Cuproptosis, a novel pathway of regulated cell death as a therapeutic target in treatment-naïve and targeted therapy-res...

    Call: OPUS 25 , Panel: NZ5

    Principal investigator: dr hab. Mariusz Łukasz Hartman

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  41. Targeting Energy Metabolism for Precision Cancer Therapy: Novel Inhibitors of LDH-A and PDK1 as Potential Strategies to ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Marika Anna Frańczak

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  42. The Role of the Mitochondrial Unfolded Protein Response (UPRmt) in Endothelial Function: a Possible Novel Target for the...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Sylwester Tycjan Mosiołek

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  43. Conjugates of peptide nucleic acids with aminoglycosides and fluoroquinolones as a novel strategy to target multi-drug r...

    Call: PRELUDIUM 22 , Panel: ST5

    Principal investigator: Izabela Siekierska

    Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego

  44. Senolytic nanoplatform to target and eliminate skin cancer Zombie cells

    Call: WEAVE-UNISONO , Panel: ST5

    Principal investigator: dr hab. Anna Lewińska

    Uniwersytet Rzeszowski

  45. Targeted inhibition of hypusination pathway

    Call: OPUS 24 , Panel: NZ7

    Principal investigator: dr Przemysław Marek Grudnik

    Uniwersytet Jagielloński, Małopolskie Centrum Biotechnologii Uniwersytetu Jagiellońskiego

  46. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Adam Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  47. Research on the preparation of new, hydrogel nanosystems for targeted therapy of colorectal cancer

    Call: SONATA 18 , Panel: NZ7

    Principal investigator: dr Urszula Helena Piotrowska

    Warszawski Uniwersytet Medyczny

  48. Customized DNA-based nanocarriers to boost heart healing

    Call: WEAVE-UNISONO , Panel: NZ7

    Principal investigator: dr Monika Bzowska

    Uniwersytet Jagielloński

  49. Gaining control on XBP1s signaling as a starting point for novel cancer therapies

    Call: OPUS 24 , Panel: NZ7

    Principal investigator: prof. Rafał Artur Bartoszewski

    Uniwersytet Wrocławski, Wydział Biotechnologii

  50. Targeted drug delivery systems - synthesis and functionalization of nanocarriers

    Call: SONATA 2 , Panel: ST5

    Principal investigator: dr Krzysztof Szczepanowicz

    Instytut Katalizy i Fizykochemii Powierzchni im. Jerzego Habera Polskiej Akademii Nauk